文献速递肝病消化道肿瘤与早癌

原发性和继发性肝脏肿瘤的肝移植:患者水平荟萃分析与UNOS常规适应证比较

Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications.
PubMed 文献 · Hepatology · 2024-10-28

该研究通过4项系统综述和患者水平荟萃分析,比较肝移植治疗肿瘤学适应证(肝内胆管癌、肝门部胆管癌、神经内分泌肿瘤肝转移和结直肠癌肝转移)与UNOS数据库中常规适应证的数据。结果显示肿瘤学适应证的5年总生存率分别为53.3%、56.4%、68.6%和53.8%,在Mantel-Cox一对一比较中优于联合肝移植、二次和三次肝移植,与70岁以上和高BMI受者的肝移植无统计学显著差异。

要点

  • 肿瘤学适应证肝移植5年总生存率分别为肝内胆管癌53.3%、肝门部胆管癌56.4%、神经内分泌肿瘤肝转移68.6%、结直肠癌肝转移53.8%。
  • 在Mantel-Cox一对一比较中,肿瘤学适应证生存优于联合肝移植、二次和三次肝移植。
  • 肿瘤学适应证与70岁以上和高BMI受者的肝移植生存无统计学显著差异。

核心结论

  • 肿瘤学适应证肝移植具有足够的5年生存率,尤其是在文献可用选择标准下进行时(肝门部胆管癌采用类Mayo方案、结直肠癌肝转移采用SECA-2、神经内分泌肿瘤采用米兰标准)。
  • 尽管对等待名单影响存在担忧,其他一些肝移植适应证的生存率更低;这些肿瘤患者应在经过验证的标准内获得确定性治愈性治疗的机会。

研究设计与样本

  • 研究进行了4项系统综述,纳入所有关于肿瘤学适应证(肝内胆管癌和肝门部胆管癌)及神经内分泌肿瘤和结直肠癌肝转移的系列研究,并采用患者水平荟萃分析与UNOS数据库常规日常实践适应证数据进行比较。
  • 对特定选择标准(肝门部胆管癌的类Mayo方案、结直肠癌肝转移的SECA-2、神经内分泌肿瘤的米兰标准)进行了二次分析。
  • 分析了2005年至2020年UNOS数据库中的112,014例肝移植,并与荟萃分析获得的肝内胆管癌345例、肝门部胆管癌721例、神经内分泌肿瘤肝转移494例和结直肠癌肝转移103例患者进行比较。

主要发现

  • 肝内胆管癌、肝门部胆管癌、神经内分泌肿瘤肝转移和结直肠癌肝转移的5年总生存率分别为53.3%、56.4%、68.6%和53.8%。
  • 在Mantel-Cox一对一比较中,肿瘤学适应证的生存优于联合肝移植、二次和三次肝移植。
  • 在Mantel-Cox一对一比较中,肿瘤学适应证的生存与70岁以上和高BMI受者的肝移植无统计学显著差异。

关键数值与推荐

  • 肝门部胆管癌采用类Mayo方案选择标准。
  • 结直肠癌肝转移采用SECA-2选择标准。
  • 神经内分泌肿瘤肝转移采用米兰标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Liver transplant (LT) for transplant oncology (TO) indications is being slowly adopted worldwide and has been recommended to be incorporated cautiously due to concerns about mid-long-term survival and its impact on the waiting list. APPROACH AND RESULTS: We conducted 4 systematic reviews of all series on TO indications (intrahepatic cholangiocarcinoma and perihilar cholangiocarcinoma [phCC]) and liver metastases from neuroendocrine tumors (NETs) and colorectal cancer (CRLM) and compared them using patient-level meta-analyses to data obtained from the United Network for Organ Sharing (UNOS) database considering conventional daily-practice indications. Secondary analyses were done for specific selection criteria (Mayo-like protocols for phCC, SECA-2 for CRLM, and Milan criteria for NET). A total of 112,014 LT were analyzed from 2005 to 2020 from the UNOS databases and compared with 345, 721, 494, and 103 patients obtained from meta-analyses on intrahepatic cholangiocarcinoma and phCC, and liver metastases from NET and CRLM, respectively. Five-year overall survival was 53.3%, 56.4%, 68.6%, and 53.8%, respectively. In Mantel-Cox one-to-one comparisons, survival of TO indications was superior to combined LT, second, and third LT and not statistically significantly different from LT in recipients >70 years and high BMI. CONCLUSIONS: Liver transplantation for TO indications has adequate 5-year survival rates, mostly when performed under the selection criteria available in the literature (Mayo-like protocols for phCC, SECA-2 for CRLM, and Milan for NET). Despite concerns about its impact on the waiting list, some other LT indications are being performed with lower survival rates. These oncological patients should be given the opportunity to have a definitive curative therapy within validated criteria.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ciria R, Ivanics T, Aliseda D, et al. Liver transplantation for primary and secondary liver tumors: Patient-level meta-analyses compared to UNOS conventional indications. Hepatology. 2024. PMID: 39465987. doi:10.1097/HEP.0000000000001129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。